| Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia G Saglio, DW Kim, S Issaragrisil, P Le Coutre, G Etienne, C Lobo, ... New England Journal of Medicine 362 (24), 2251-2259, 2010 | 2091 | 2010 |
| A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias JE Cortes, DW Kim, J Pinilla-Ibarz, P Le Coutre, R Paquette, C Chuah, ... New England Journal of Medicine 369 (19), 1783-1796, 2013 | 1229 | 2013 |
| Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia … HM Kantarjian, F Giles, N Gattermann, K Bhalla, G Alimena, F Palandri, ... Blood, The Journal of the American Society of Hematology 110 (10), 3540-3546, 2007 | 961 | 2007 |
| Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial A Hochhaus, G Saglio, TP Hughes, RA Larson, DW Kim, S Issaragrisil, ... Leukemia 30 (5), 1044-1054, 2016 | 873 | 2016 |
| Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification P le Coutre, E Tassi, M Varella-Garcia, R Barni, L Mologni, G Cabrita, ... Blood, The Journal of the American Society of Hematology 95 (5), 1758-1766, 2000 | 703 | 2000 |
| Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib C Gambacorti-Passerini, L Antolini, FX Mahon, F Guilhot, M Deininger, ... Journal of the National Cancer Institute 103 (7), 553-561, 2011 | 517 | 2011 |
| Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial JE Cortes, DW Kim, J Pinilla-Ibarz, PD le Coutre, R Paquette, C Chuah, ... Blood, The Journal of the American Society of Hematology 132 (4), 393-404, 2018 | 510 | 2018 |
| Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results HM Kantarjian, FJ Giles, KN Bhalla, J Pinilla-Ibarz, RA Larson, ... Blood, The Journal of the American Society of Hematology 117 (4), 1141-1145, 2011 | 506 | 2011 |
| European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia JL Steegmann, M Baccarani, M Breccia, LF Casado, V García-Gutiérrez, ... Leukemia 30 (8), 1648-1671, 2016 | 493 | 2016 |
| In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor P Le Coutre, L Mologni, L Cleris, E Marchesi, E Buchdunger, R Giardini, ... Journal of the National Cancer Institute 91 (2), 163-168, 1999 | 491 | 1999 |
| Role of α1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571 C Gambacorti-Passerini, R Barni, P le Coutre, M Zucchetti, G Cabrita, ... Journal of the National Cancer Institute 92 (20), 1641-1650, 2000 | 490 | 2000 |
| Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial JE Cortes, C Gambacorti-Passerini, MW Deininger, MJ Mauro, C Chuah, ... Journal of Clinical Oncology 36 (3), 231, 2018 | 479 | 2018 |
| Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis C Gambacorti-Passerini, P Le Coutre, L Mologni, M Fanelli, C Bertazzoli, ... Blood Cells, Molecules, and Diseases 23 (3), 380-394, 1997 | 457 | 1997 |
| Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic … P Le Coutre, OG Ottmann, F Giles, DW Kim, J Cortes, N Gattermann, ... Blood, The Journal of the American Society of Hematology 111 (4), 1834-1839, 2008 | 380 | 2008 |
| Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure TP Hughes, MJ Mauro, JE Cortes, H Minami, D Rea, DJ DeAngelo, ... New England Journal of Medicine 381 (24), 2315-2326, 2019 | 344 | 2019 |
| Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study A Hochhaus, T Masszi, FJ Giles, JP Radich, DM Ross, ... Leukemia 31 (7), 1525-1531, 2017 | 303 | 2017 |
| Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors P Valent, E Hadzijusufovic, GH Schernthaner, D Wolf, D Rea, P le Coutre Blood, The Journal of the American Society of Hematology 125 (6), 901-906, 2015 | 299 | 2015 |
| Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study FJ Giles, PD Le Coutre, J Pinilla-Ibarz, RA Larson, N Gattermann, ... Leukemia 27 (1), 107-112, 2013 | 291 | 2013 |
| Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib TD Kim, D Rea, M Schwarz, P Grille, FE Nicolini, G Rosti, L Levato, ... Leukemia 27 (6), 1316-1321, 2013 | 284 | 2013 |
| Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial JH Lipton, C Chuah, A Guerci-Bresler, G Rosti, D Simpson, S Assouline, ... The Lancet Oncology 17 (5), 612-621, 2016 | 263 | 2016 |
